Specimen Analysis

Researchers apply to the PPMI Biospecimen Review Committee (BRC) to request PPMI samples for biomarker verification studies. Research studies approved for the use of these samples are included below. Search the PPMI specimen analysis projects by entering your terms below.
Project Title Principal Investigator Institution Specimen Used
Association of cerebrospinal fluid ?-amyloid 1-42, T-tau, P-tau181, and ?-synuclein levels with clinical features of drug-naive patients with early Parkinson disease PPMI Bioanalytics Core PPMI Steering Committee Cerebrospinal Fluid
Clinical, imaging, and plasma and CSF correlates of alpha-synuclein genomic variability Matthew Farrer, PhD University of British Columbia (UBC) DNA
Evaluation of PD-linked Transcripts in PPMI Clemens R. Scherzer, M.D. Harvard University RNA
Genetic risks for Parkinson???s disease and disease progression: genotyping of the PPMI cohort PPMI Genetics Core PPMI Steering Committee DNA
Insulin-like growth factor-1 and DAT imaging as biomarkers of early cognitive impairment in Parkinson's disease Maria Teresa Pellecchia, MD University of Salerno Serum
Plasma Apolipoprotein A1 Level as a Biomarker in Parkinson's Disease Alice Chen-Plotkin, MD, MSc University of Pennsylvania Plasma
Whole Blood RNA Biomarkers of Parkinson's Disease Judith Potashkin, PhD Rosalind Franklin University of Medicine and Science RNA